Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development	$ 14,113	$ 18,903
General and administrative	19,104	17,044
Restructuring, impairment and other costs of terminated programs	2,963
Total operating expenses	36,180	35,947
Loss from operations	(36,180)	(35,947)
Interest income	575	126
Net loss	$ (35,605)	$ (35,821)
Net loss per share-basic	$ (1.66)	$ (1.69)
Net loss per share-diluted	$ (1.66)	$ (1.69)
Weighted-average number of shares outstanding used in computing net loss per share-basic	21,489,280	21,199,291
Weighted-average number of shares outstanding used in computing net loss per share-diluted	21,489,280	21,199,291